Compare AbbVie Inc (ABBV) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Raytheon Technologies Corp — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Raytheon Technologies Corp trades at $194.65 (market cap $270.48B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | RTX | |
|---|---|---|
Market Cap | $449.91B | $270.48B |
Sector | Health | Industrials |
52-Week High | $261.07 | $212.16 |
52-Week Low | $184.85 | $144.91 |
Enterprise Value | $513.38B | $302.60B |
Dividend Yield | 2.72% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
RTX trades at $201.37, up 1.06% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a $515 million Navy contract for SPY-6 radars highlight operational momentum. Revenue grew to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock is near its consensus price target of $213, with no sell ratings among 26 analysts.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation multiples and geopolitical dependencies. Upside potential exists if the company maintains its earnings beat streak and capitalizes on increased defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
